Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Business and period: This unaudited report covers the three months ended December 31, 2023, the company’s fiscal first quarter of 2024. Citius is a development-stage biopharmaceutical company focused on oncology, anti-infectives, prescription products, and stem cell therapies. It reported no operating revenue in the quarter or the comparable prior-year quarter.
Financial performance and liquidity
| Metric | Three months ended Dec. 31, 2023 | Prior-year comparable period |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.62 million | $3.45 million |
| General and administrative expense | $3.66 million | $2.60 million |
| Stock-based compensation | $3.06 million | $1.20 million |
| Operating loss | $9.34 million | $7.25 million |
| Net loss | $9.23 million, or $0.06 per share | $3.59 million, or $0.02 per share |
| Cash used in operating activities | $6.14 million | $4.82 million |
Interest income was $254,000 versus $215,000. The prior-year quarter included a $3.59 million gain from selling New Jersey tax net operating losses; no such gain was recorded this quarter. The company attributed the higher net loss mainly to increased G&A and stock compensation and the absence of that prior-year gain. R&D fell, principally due to lower Mino-Lok and Halo-Lido costs.
Cash and cash equivalents were $20.35 million at December 31, 2023, down from $26.48 million at September 30, 2023. Working capital was approximately $22.6 million. Total liabilities were $12.07 million; the filing reports operating lease liabilities and a deferred tax liability, but no conventional borrowings. No meaningful operating margin can be assessed because the company had no revenue. Accumulated deficit was $171.46 million.
Material developments and outlook
- Going concern: Management estimated available cash would fund operations through August 2024. The filing states this raises substantial doubt about the company’s ability to continue as a going concern within one year after the financial statements were issued. Additional capital, strategic arrangements, or product revenue will be needed; none is assured.
- LYMPHIR: The FDA issued a Complete Response Letter in July 2023 requiring enhanced product testing and additional controls; the filing says the FDA raised no concerns about the clinical safety and efficacy data and did not request additional trials. Citius filed a BLA resubmission on February 13, 2024, after quarter-end.
- Mino-Lok: The company reported completing enrollment in its pivotal Phase 3 trial on January 2, 2024, after quarter-end: 241 patients were enrolled and 109 catheter-failure events observed, exceeding the 92-event minimum.
- Spinoff/merger: Under an October 2023 agreement, Citius Oncology is to combine with TenX Keane Acquisition and become part of a publicly traded company named Citius Oncology, Inc. The transaction was expected to close in the first half of 2024, subject to approvals and other conditions. Citius Pharma would receive 67.5 million shares and contribute $10 million in cash; completion was not assured.
- Management expected R&D expense to stabilize in fiscal 2024 as it focuses on LYMPHIR commercialization, Mino-Lok trial completion, and Halo-Lido planning. These plans depend on regulatory outcomes and financing.
- The company terminated its Mino-Wrap license in December 2023. It also disclosed a Nasdaq minimum-bid-price deficiency, with a compliance deadline of March 11, 2024; a reverse split could be required to regain compliance.
Risks, contingencies, and capital structure
Key risks include clinical and regulatory execution, commercialization and market acceptance, the ability to raise capital, and completing the proposed transaction. Product licenses also carry potential milestone, royalty, and sublicense-payment obligations, including substantial amounts if development, approval, or sales milestones are achieved. At quarter-end, 50.7 million warrants and 17.4 million parent-company stock options were outstanding, with an additional 7.65 million shares available for future grants; these represent potential dilution. The company reported no legal proceedings and no material changes to the risk factors in its fiscal 2023 Form 10-K. Management concluded disclosure controls were effective.
Important facts for investors to verify
- Current cash, cash burn, financing plans, and the company’s ability to fund operations beyond the stated August 2024 runway.
- FDA status and timing of the LYMPHIR BLA resubmission review, and any additional testing or manufacturing requirements.
- Mino-Lok Phase 3 results and timing of data availability; confirm the post-quarter enrollment and event-count disclosures.
- Status and final terms of the proposed Citius Oncology transaction, including the $10 million contribution and any effect on Citius Pharma’s liquidity.
- Nasdaq listing compliance and potential reverse-split action, as well as warrant and option dilution.